Research peptide article

Retatrutide, Tirzepatide, and Semaglutide: How the Incretin Class Compares

Published June 9, 2026 · PX-Labs

For laboratory and research reference only. All compounds discussed are sold strictly for scientific research purposes and are not intended for human or veterinary use.

Overview

Three synthetic peptides dominate current incretin-class research: semaglutide, tirzepatide, and retatrutide. Each represents a distinct generation of receptor-targeting design — single, dual, and triple agonism respectively — and understanding what separates them at the structural level is foundational to any comparative study of this peptide class.

This article covers what each compound is, how their receptor profiles differ, and why researchers studying the incretin axis frequently examine all three in the same context.

The Incretin Class: A Brief Primer

Incretins are peptide hormones involved in metabolic signaling. The receptor targets relevant to this class — GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon — are the three axes around which modern incretin-class research peptides are designed.

The synthetic analogs in this class are classified primarily by how many of these receptors they target and the selectivity profile of that targeting. That classification — single, dual, triple — is the most useful organizing principle for comparative research.

Semaglutide: Single GLP-1 Agonist

Semaglutide is a GLP-1 receptor agonist. It targets one receptor — GLP-1 — making it the simplest member of the class from a receptor-activity standpoint.

Structurally, semaglutide is a modified analog of native GLP-1(7-36), with amino acid substitutions that improve proteolytic stability and a C-18 fatty diacid chain attached via a linker to lysine at position 26. This modification enables albumin binding, which accounts for its extended half-life relative to native GLP-1.

As a single-agonist compound, semaglutide is frequently used as a baseline in comparative receptor studies — the reference point against which dual and triple agonists are measured. Researchers comparing receptor-activity breadth across the class typically start with semaglutide to establish the single-axis reference.

Receptor profile

GLP-1 agonist (single)

Structural class

Modified GLP-1 analog, acylated

Available from PX-Labs

5mg, 10mg

Tirzepatide: Dual GIP/GLP-1 Agonist

Tirzepatide adds GIP-receptor activity to GLP-1 agonism, making it a dual agonist. It is structurally distinct from semaglutide: rather than being a modified GLP-1 analog, tirzepatide is based on a GIP analog scaffold with modifications that confer GLP-1 receptor activity alongside GIP activity.

This dual-receptor design is the feature that distinguishes tirzepatide from semaglutide in research contexts. The GIP receptor is a separate signaling axis from GLP-1, and the interaction between simultaneous GIP and GLP-1 agonism is itself a subject of active study. Researchers examining whether combined GIP/GLP-1 activity produces different outcomes than GLP-1 alone position tirzepatide as the dual-agonist test compound in that experimental framework.

The fatty acid modification on tirzepatide similarly enables albumin binding and extended half-life, using a C20 fatty diacid chain.

Receptor profile

GIP + GLP-1 agonist (dual)

Structural class

Modified GIP analog with dual-receptor activity

Available from PX-Labs

5mg, 10mg

Retatrutide: Triple GLP-1/GIP/Glucagon Agonist

Retatrutide extends the dual-agonist design by adding glucagon-receptor agonism — making it a triple agonist across GLP-1, GIP, and glucagon. This three-receptor profile is the defining characteristic of retatrutide and the primary reason it sits at the frontier of current incretin research.

The glucagon receptor is a third, distinct signaling axis. Glucagon activity modulates hepatic glucose output and energy expenditure through mechanisms separate from the insulinotropic pathways engaged by GLP-1 and GIP. Adding glucagon agonism to the dual-agonist framework creates a compound with a more complex multi-axis receptor interaction profile than either of its predecessors.

Structurally, retatrutide is a peptide with an acyl chain modification enabling albumin binding, similar in principle to the modifications used in semaglutide and tirzepatide to extend circulating half-life.

The research interest in retatrutide lies specifically in whether the addition of glucagon agonism to GIP/GLP-1 dual agonism produces a meaningfully different receptor interaction profile — and what that implies for the study of multi-receptor incretin signaling.

Receptor profile

GLP-1 + GIP + glucagon agonist (triple)

Structural class

Triple-agonist acylated peptide

Available from PX-Labs

5mg, 10mg, 30mg

Comparing the Three: Receptor Profiles Side by Side

The table captures the essential structural progression: each generation adds one receptor axis. This is why researchers studying the incretin class frequently acquire all three — to run controlled comparisons across the single/dual/triple spectrum using compounds with otherwise similar structural classes (all three are acylated peptides with albumin-binding modifications).

Why Researchers Study These Together

The incretin class offers a relatively rare opportunity in peptide research: three well-characterized compounds that differ primarily in receptor-targeting breadth, with otherwise comparable structural modifications. That makes controlled comparative study tractable in a way it often isn’t when comparing peptides from entirely different structural classes.

Common research designs in this space include:

• Receptor-selectivity studies — characterizing binding affinity and potency at each receptor, comparing single vs. dual vs. triple agonism at the molecular level
• Signaling-pathway studies — examining downstream signaling cascades from each receptor and how simultaneous multi-receptor engagement affects those pathways
• Structural analog research — using these compounds as reference molecules when developing or evaluating novel incretin-class analogs

Purity and Supply at PX-Labs

All three compounds are available from PX-Labs as lyophilized powder, tested to ≥98% purity by HPLC, with third-party COAs available on request.

• Semaglutide — 5mg, 10mg
• Tirzepatide — 5mg, 10mg
• Retatrutide — 5mg, 10mg, 30mg

Bacteriostatic water for reconstitution is available separately as an accessory.

Research Use Only

All compounds discussed in this article are sold strictly for laboratory and scientific research. They are not intended for human or veterinary use. PX-Labs is a research chemical supplier, not a compounding pharmacy, and does not provide usage, dosing, or application guidance.